Central Nervous System Lymphoma
📧 Sign up to get email alerts when something new happens for Central Nervous System Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) [Phase 1, Phase 2]
Phase 1/2 LOC-R01 study evaluates lenalidomide and ibrutinib in combination with Rituximab-Methotrexate-Procarbazine-Vincristine (R-MPV) for…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） [NA]
Clinical trial evaluating the efficacy and safety of combining methotrexate or thiotepa or temozolomide with orelabrutinib and selinexor in …
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL [Phase 2, Phase 3]
This document reports a planned Phase 2/3 clinical trial evaluating Orelabrutinib combined with teniposide, rituximab, and methotrexate for …
-
CLINICAL_TRIALS trial_result · 2025-09-16Clinical Trial Update: New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen
A completed clinical trial investigating the treatment of newly diagnosed primary central nervous system lymphoma with methotrexate plus an …
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Selinexor in Combination With MTX+Ritu to Treat R/R CNSL [Phase 1, Phase 2]
A Phase 1/2 clinical trial (NCT05698147) is evaluating selinexor in combination with methotrexate and rituximab for relapsed/refractory cent…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma [Phase 1]
Phase 1 clinical trial evaluating [18F]-Fludarabine PET/MRI in primary CNS lymphoma has completed.
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma [Phase 1]
Phase 1 trial update on cord blood-derived CAR-NK cells targeting CD19 for refractory/recurrent central nervous system lymphoma; the study i…
-
CLINICAL_TRIALS research · 2025-08-13Clinical Trial Update: Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL [Phase 2]
This entry notes a Phase 2 clinical trial at the University of Cologne evaluating the combination of methotrexate, tafasitamab, lenalidomide…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]
This Clinical Trial Update describes a fourth-generation CD19/CD22 dual-targeting CAR T-cell therapy being evaluated in Phase 1/2 for highly…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of selinexor, temozolomide, and an anti-PD-1 antibody for relapsed/refractory primary …
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Axi-cel in CNS Lymphoma [Phase 1]
Phase 1 study of axicabtagene ciloleucel in CNS lymphoma is active but not recruiting, with Dana-Farber as sponsor.
-
CLINICAL_TRIALS research · 2025-07-20Clinical Trial Update: Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL [NA]
This clinical trial is evaluating a combination of teniposide, a PD-1 monoclonal antibody, and selinixor for relapsed or refractory primary …
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma [Phase 1]
Phase 1 clinical trial investigating intracerebroventricular administration of autologous CD19 CAR T cells for central nervous system lympho…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL [Phase 2]
Phase 2 clinical trial of Paxalisib (GDC-0084) for recurrent or refractory primary central nervous system lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
The CLIMB study, conducted by Royal Marsden NHS Foundation Trust, investigates imaging and molecular biomarkers for central nervous system l…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma [Phase 2]
Phase 2 clinical trial evaluating high-dose chemotherapy with gemcitabine, busulfan, and thiotepa followed by autologous stem cell transplan…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.
This clinical trial update indicates ongoing recruitment for a study aiming to improve safety and accuracy of stereotactic brain biopsies in…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
This completed clinical trial investigates the potential role of surgical resection and stereotactic radiosurgery in treating primary centra…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response [Phase 2]
Phase 2 trial evaluating maintenance obinutuzumab in patients with primary central nervous system lymphoma who have achieved a complete or p…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas [Phase 2]
Phase 2 pilot study evaluating acalabrutinib in relapsed or refractory central nervous system lymphomas; the trial is currently active but n…
-
CLINICAL_TRIALS other · 2025-06-03Clinical Trial Update: Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study [Phase 2]
Phase II open-label, single-arm multicenter study evaluating a combination of selinexor, high-dose methotrexate, and rituximab with radiothe…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL [Phase 1]
Phase I trial evaluating tolerability, safety, pharmacokinetics, and preliminary efficacy of combining ONO-4059 with the R-MPV regimen for p…
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Diagnosis; Objective RespOnse; THErApy [NA]
A clinical trial sponsored by IRCCS San Raffaele is currently recruiting for Primary Central Nervous System Lymphoma; no results reported ye…
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. [Phase 1]
A Phase 1 clinical trial update for a combination of rituximab, acalabrutinib, and durvalumab (RAD) in primary central nervous system lympho…
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma [Phase 1]
This is a Phase 1 trial update evaluating zanubrutinib in combination with Pola-R-CHP and high-dose methotrexate for secondary central nervo…